GlassScriptPhysician profile
Melvin Theodore Vidal
NPI 1538267679
$1,741.69
in general payments reported to CMS, 2019-2025
16 companies · $547 in 2025
The $547 reported for 2025 was more than what 91% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $539 · 2024: $657 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $538.70 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.52 | 2023-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $202.51 | 2024-2025 | Zerbaxa, Dificid, Recarbrio |
| Novartis Pharmaceuticals Corporation | $150.51 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $115.71 | 2023-2024 | Xarelto |
| Alexion Pharmaceuticals, INC. | $84.23 | 2023-2025 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.71 | 2025 | Xifaxan |
| Electromed, INC. | $57.16 | 2023 | Smartvest |
| E.R. Squibb & Sons, L.L.C. | $55.73 | 2023-2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $52.23 | 2023-2024 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $49.18 | 2024 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $34.15 | 2023-2024 | Andexxa |
| Sk Life Science, INC. | $32.86 | 2025 | |
| Paratek Pharmaceuticals, INC. | $24.98 | 2023 | Nuzyra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.07 | 2025 | Lifevest |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $19.44 | 2025 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Vidal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.